• Adding Pembrolizumab to Docetaxel Fails to Improve Survival in mCRPC

    13 days ago - By MedPageToday

    The addition of pembrolizumab to docetaxel for patients with metastatic castration-resistant prostate cancer did not improve overall or radiographic progression-free survival versus docetaxel alone in the phase...
    Read more ...